<DOC>
	<DOCNO>NCT02388737</DOCNO>
	<brief_summary>This comparative study vonoprazan ( TAK-438 ) ( 10 mg 20 mg ) participant endoscopic heal erosive esophagitis confirm vonoprazan adequate treatment proton pump inhibitor ( PPI ) , demonstrate non-inferiority vonoprazan lansoprazole maintenance treatment ( 6 month 24 week ) well determine clinically recommend dose vonoprazan maintenance therapy erosive esophagitis .</brief_summary>
	<brief_title>Efficacy Safety Vonoprazan Compared Lansoprazole Maintenance Treatment Erosive Esophagitis</brief_title>
	<detailed_description>The drug test study call vonoprazan . Vonoprazan test maintenance treatment people heal erosive esophagitis ( EE ) . This study look participant endoscopic heal erosive esophagitis confirm vonoprazan adequate treatment proton pump inhibitor ( PPI ) , demonstrate non-inferiority vonoprazan Lansoprazole maintenance treatment ( 6 month 24 week ) well determine clinically recommend dose vonoprazan maintenance therapy erosive esophagitis . The study enroll approximately 693 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - TAK-438 10 mg - TAK-438 20 mg - Lansoprazole 15 mg Participants ongoing erosive esophagitis ( EE ) receive lansoprazole 30 mg daily 4 8 week ( Healing phase ) heal EE confirm endoscopy perform either Week -4 and/or Day 1 eligible randomization maintenance phase . In Maintenance phase , participant confirm EE healing ask take 2 tablet capsule time morning breakfast throughout study . All participant ask record daytime nighttime ( sleep ) subjective symptom diary daily basis . This multi-centre trial conduct worldwide . The overall time participate study 8 month . Participants make multiple visit clinic , contact telephone 7-14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has confirm endoscopy erosive esophagitis [ Los Angeles ( LA ) classification grade A D ] within 84 day Day 1 . 4 . If participant roll TAK438_303 study , he/she undergone openlabel Proton pump inhibitor ( PPI ) treatment ( Lansoprazole 30 mg , daily ) 4 8 week within TAK438_305 protocol . 5 . Has confirm endoscopy heal erosive esophagitis . This endoscopy , part TAK438_303 study , must within last 14 day prior randomization , otherwise endoscopy must repeat confirm heal randomization TAK438_305 study . 6 . Is age 18 year old old ( local age consent older ) , male female , time signing informed consent , treat outpatient basis erosive esophagitis , include temporarily admit examination . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 4 week last dose study medication . 1 . Has receive investigational compound ( study TAK438_303 ) within 84 day prior screen phase . 2 . Has receive TAK438 previous clinical study ( study TAK438_303 ) therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has , judgment investigator , clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes Screening . 5 . Has history clinical manifestation significant central nervous system ( CNS ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urological , endocrine hematological disease . 6 . Has history hypersensitivity allergy TAK438 proton pump inhibitor ( PPIs ) include associate excipients . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior start screen phase . 8 . Is required take exclude medication . 9 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 10 . Has participate another clinical study ( study TAK438_303 ) within past 30 day Visit 1 . 11 . Has comorbidities could affect esophagus ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiotherapy cryotherapy esophagus ; corrosive physiochemical injury ( possible inclusion study Schatzki 's ring Barrett 's esophagus ) . 12 . Has history surgical procedure may affect esophagus ( eg , fundoplication mechanical dilatation esophageal strictures exclude Schatzki 's ring ) history gastric duodenal surgery exclude endoscopic removal benign polyp . 13 . Developed acute upper gastrointestinal bleeding , gastric ulcer ( mucosal defect white coating ) duodenal ulcer ( mucosal defect white coating ) , within 30 day start Screening Phase ( Visit 1 ) ( possible inclusion gastric duodenal erosion ) . Participants require nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin treatment along concomitant PPI therapy prevent gastrointestinal ( GI ) bleeding enrol . 14 . Has ZollingerEllison syndrome gastric acid hypersecretion history gastric acid hypersecretion . 15 . Is schedule surgery require hospitalization require surgical treatment his/her participation study . 16 . Has history malignancy treat malignancy within 5 year start Screening Phase ( visit 1 ) ( participant may include study he/she cure cutaneous basal cell carcinoma cervical carcinoma situ ) . 17 . Has acquire immunodeficiency syndrome ( AIDS ) hepatitis , include hepatitis virus carrier ( hepatitis B surface antigen [ HBsAg ] hepatitis C virus ( HCV ) antibodypositive ) ( participant may include study he/she HCVantigen HCVribonucleic acid [ RNA ] negative ) . 18 . Laboratory test perform visit 1 reveal follow abnormality participant : 1 . Creatinine level : &gt; 2 mg/dL ( &gt; 177 μmol/L ) . 2 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , total bilirubin level : &gt; upper limit normal ( ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>